+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Allergy Drugs Market - Global Forecast 2026-2032- Product Image
Allergy Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Allergy Drugs Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5264366
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Allergy Drugs Market is projected to reach USD 27.08 Billion in 2026. It is expected to continue growing at a CAGR of 6.67%, reaching USD 40.03 Billion by 2032.

Allergy drugs are moving from seasonal symptom control to year-round management of chronic, immune-mediated disease. Demand is supported by the high prevalence of allergic rhinitis, urticaria, asthma-associated allergy, food allergy, and anaphylaxis risk. The World Allergy Organization reports allergic rhinitis affects 10% to 30% of adults and up to 40% of children, while the CDC reports more than one-quarter of U.S. adults had seasonal allergies in 2021.

The allergy drugs market is anchored by oral antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, mast-cell stabilizers, decongestants, epinephrine auto-injectors, allergen immunotherapy, and biologics targeting IgE and type 2 inflammation. Competitive advantage increasingly depends on rapid relief, safety, adherence, pediatric suitability, payer access, and evidence in comorbid allergic disease.

Transformative Shifts in Allergy Treatment and Access

The landscape is being reshaped by a shift from broad symptomatic therapies toward precision treatment pathways. Second-generation antihistamines and intranasal corticosteroids remain first-line options for allergic rhinitis, but biologics used in severe asthma, chronic spontaneous urticaria, atopic dermatitis, and nasal polyps are changing expectations for refractory allergy care.

Consumer behavior is also transforming the market. Over-the-counter access, telehealth prescribing, direct-to-consumer allergy testing, and home delivery are making treatment more convenient, while regulators and payers continue to scrutinize safety, real-world outcomes, and cost effectiveness. Climate-driven pollen season changes are further increasing the need for durable allergy management strategies, as peer-reviewed research links warmer temperatures and higher carbon dioxide levels with longer pollen seasons and increased pollen production in many regions.

Cumulative Impact of Artificial Intelligence on Allergy Drugs

Artificial intelligence is beginning to influence allergy drug discovery, trial design, pharmacovigilance, and patient engagement. AI-enabled analysis of genomic, proteomic, claims, electronic health record, pollen, air-quality, and weather data can help identify patient subgroups, predict exacerbation risk, and support more targeted use of antihistamines, corticosteroids, immunotherapy, epinephrine, and biologics.

The cumulative impact will depend on clinical validation, data quality, bias controls, cybersecurity, and regulatory acceptance. AI can improve signal detection in adverse-event databases and optimize trial recruitment for allergic rhinitis, urticaria, asthma-related allergy, and food allergy, but commercial value will come from clinically interpretable tools that improve adherence, reduce avoidable acute care, and demonstrate measurable patient outcomes.

Key Regional Insights Across the Allergy Drugs Market

Asia-Pacific is a high-opportunity region due to urbanization, air pollution exposure, expanding middle-class healthcare spending, and increasing diagnosis of allergic rhinitis, asthma, and food allergy. China, India, Japan, South Korea, and Australia are central to demand for antihistamines, intranasal corticosteroids, epinephrine products, allergen immunotherapy, and biologics, although access varies by reimbursement, local guidelines, diagnostic capacity, and specialist availability.

North America remains a leading allergy drugs market because of high allergy prevalence, strong over-the-counter channels, biologic adoption, established epinephrine auto-injector use, and broad public-private insurance coverage. Europe benefits from established allergen immunotherapy use, pharmacovigilance standards, respiratory-allergy guidelines, and cross-border regulatory alignment, while Latin America shows rising demand in Brazil and Mexico as private healthcare, retail pharmacy networks, and branded-generic access expand. The Middle East, led by GCC countries, combines dust exposure, heat, indoor allergen burden, and urban air-quality challenges with growing specialty care investment. Africa remains underpenetrated, with opportunity tied to diagnosis, affordability, physician training, reliable medicine supply, and access to essential allergy and anaphylaxis treatments.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are characterized by rising urban allergy burden, strong retail pharmacy penetration, tropical aeroallergen exposure, and uneven access to specialist-led diagnosis and allergen immunotherapy. GCC countries show demand for premium prescription allergy drugs, biologics, epinephrine products, and respiratory-allergy care as healthcare systems invest in specialty clinics, digital health infrastructure, and chronic-disease management programs.

The European Union remains important for allergen immunotherapy, pharmacovigilance, clinical guideline adoption, medicine safety monitoring, and biosimilar policy, while BRICS economies combine large untreated patient pools with growing domestic pharmaceutical manufacturing and expanding access to branded generics and specialty medicines. G7 markets account for significant innovation, reimbursement complexity, regulatory oversight, and clinical-trial activity across antihistamines, corticosteroids, biologics, and food allergy interventions. NATO countries overlap heavily with high-income allergy drug markets where supply security, regulatory resilience, essential medicine availability, and cold-chain dependability are increasingly strategic priorities.

Key Country Insights for Allergy Drug Commercial Strategy

The United States leads in OTC allergy medicines, biologics, digital care, and epinephrine auto-injector demand, supported by CDC-documented seasonal allergy prevalence and extensive retail pharmacy access. Canada emphasizes guideline-based care, public-private reimbursement, and equitable access considerations, while Mexico and Brazil offer expanding retail, branded-generic, and private-care opportunities supported by rising awareness of allergic rhinitis and asthma-related allergy. The United Kingdom, Germany, France, Italy, and Spain provide mature markets with strong use of intranasal corticosteroids, second-generation antihistamines, and allergen immunotherapy; Germany and France are also notable for structured specialty care, while the United Kingdom emphasizes evidence-based prescribing and pharmacy access. Russia remains shaped by affordability, reimbursement limits, and local supply dynamics.

China and India are major growth engines because of population scale, urban air pollution, increasing respiratory symptoms, expanding healthcare access, and improving availability of prescription therapies. Japan and South Korea offer advanced diagnostics, strong clinical infrastructure, and innovation capacity, especially in biologics, respiratory allergy, and specialty immunology care. Australia is notable for high allergic disease awareness, established anaphylaxis protocols, food allergy research, and demand for evidence-based allergy and immunology services, supported by public health attention to severe allergic reactions and school-based risk management.

Actionable Recommendations for Allergy Drug Industry Leaders

Industry leaders should prioritize differentiated evidence in speed of symptom relief, safety, non-sedating profiles, pediatric use, adherence, real-world effectiveness, and compatibility with comorbid asthma, atopic dermatitis, chronic urticaria, and nasal polyps. Portfolio strategies should balance high-volume OTC antihistamines and intranasal sprays with specialty biologics, epinephrine access solutions, and allergen immunotherapy for disease modification.

Commercial teams should localize pricing, reimbursement, packaging, labeling, and channel strategies by market maturity. Partnerships with pollen-data platforms, air-quality services, telehealth providers, pharmacies, and payers can improve patient identification, seasonal preparedness, and retention. Manufacturers should also strengthen supply continuity for essential allergy drugs, particularly epinephrine, corticosteroids, antihistamines, and high-demand seasonal products, while maintaining pharmacovigilance and patient education on appropriate use.

Research Methodology and Data Validation Approach

This executive summary is built on secondary research from verified public-health, regulatory, clinical, and scientific sources, including the World Allergy Organization, CDC, WHO, European allergy organizations, peer-reviewed literature, product labels, clinical guidelines, regulatory databases, and pharmacovigilance resources. The analysis prioritizes prevalence, treatment pathways, safety, access, adherence, reimbursement context, and commercialization evidence.

Market interpretation combines epidemiology, therapy segmentation, regional healthcare infrastructure, reimbursement context, supply-chain considerations, regulatory pathways, and competitive dynamics. Insights were synthesized to support executive decision-making while avoiding unsupported market-size claims and emphasizing data-backed drivers relevant to allergy drugs, allergic rhinitis therapies, antihistamines, corticosteroids, decongestants, epinephrine auto-injectors, allergen immunotherapy, biologics, food allergy treatment, and anaphylaxis management.

Conclusion: Allergy Drugs Market Outlook

The allergy drugs market is expanding in strategic importance as allergic disease prevalence, climate-related exposure, urban pollution, food allergy recognition, and patient expectations increase. Established therapies will continue to define broad treatment use, while biologics, allergen immunotherapy, epinephrine access, and data-driven care models will shape value creation in more severe, persistent, and high-risk allergic conditions.

Companies that combine clinical credibility with affordable access, digital engagement, regulatory discipline, patient education, and reliable supply will be best positioned. The strongest opportunities will come from products and services that reduce symptom burden, prevent severe reactions, improve adherence, support guideline-based care, and align with payer demand for measurable outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Allergy Drugs Market, by Drug Class
7.1. Introduction
7.2. Antihistamines
7.2.1. First Generation
7.2.2. Second Generation
7.3. Corticosteroids
7.4. Decongestants
7.5. Leukotriene Receptor Antagonists
7.6. Mast Cell Stabilizers
8. Allergy Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.3. Nasal
8.3.1. Drops
8.3.2. Spray
8.4. Ophthalmic
8.5. Oral
8.6. Topical
9. Allergy Drugs Market, by Allergy Indication
9.1. Introduction
9.2. Drug Allergies
9.3. Eye Allergies
9.4. Food Allergies
9.5. Latex Allergy
9.6. Respiratory Allergies
9.6.1. Allergic Asthma
9.6.2. Allergic Rhinitis
9.7. Skin Allergies
10. Allergy Drugs Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Pediatric
11. Allergy Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Allergy Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. Allergy Drugs Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. BRICS
13.5. European Union
13.6. ASEAN
13.7. GCC
14. Allergy Drugs Market, by Country
14.1. Introduction
14.2. China
14.3. United States
14.4. Japan
14.5. India
14.6. Germany
14.7. United Kingdom
14.8. Australia
14.9. France
14.10. South Korea
14.11. Italy
14.12. Canada
14.13. Russia
14.14. Brazil
14.15. Mexico
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Alcon Inc.
16.3. ALK-Abelló A/S
16.4. Allergopharma GmbH & Co. KG
16.5. Allergy Therapeutics plc
16.6. Apotex Inc.
16.7. Bayer AG
16.8. Biomay AG
16.9. Boehringer Ingelheim International GmbH
16.10. Cipla Ltd.
16.11. Circassia Group plc
16.12. DBV Technologies S.A.
16.13. Dr. Reddy’s Laboratories Ltd.
16.14. F. Hoffmann-La Roche Ltd
16.15. Faes Farma, S.A.
16.16. Genentech, Inc.
16.17. GlaxoSmithKline plc
16.18. Glenmark Pharmaceuticals Ltd.
16.19. HAL Allergy B.V.
16.20. Inmunotek S.L.
16.21. Johnson & Johnson
16.22. LETI Pharma, S.L.U.
16.23. Meda Pharmaceuticals
16.24. Merck & Co., Inc.
16.25. Novartis AG
16.26. Pfizer Inc.
16.27. Prestige Brands Holdings Inc
16.28. Regeneron Pharmaceuticals, Inc.
16.29. Sanofi S.A.
16.30. Stallergenes Greer International AG
16.31. Sun Pharmaceutical Industries Ltd.
16.32. Teva Pharmaceutical Industries Ltd.
16.33. Torii Pharmaceutical Co., Ltd.
17. Key Experts
List of Figures
FIGURE 1. Global Allergy Drugs Market, Years Considered for the Study
FIGURE 2. Global Allergy Drugs Market, Research Design
FIGURE 3. Global Allergy Drugs Market, Research Framework
FIGURE 4. Global Allergy Drugs Market, Data Triangulation
FIGURE 5. Global Allergy Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Allergy Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Allergy Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Allergy Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Allergy Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Allergy Drugs Market Size, by Allergy Indication, 2025 vs 2032 (%)
FIGURE 11. Global Allergy Drugs Market Size, by Allergy Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Allergy Drugs Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Allergy Drugs Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Allergy Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Allergy Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Allergy Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Allergy Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Allergy Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Allergy Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Allergy Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Allergy Drugs Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Allergy Drugs Market Segmentation & Coverage
TABLE 2. Global Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Antihistamines Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antihistamines Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antihistamines Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global First Generation Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global First Generation Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global First Generation Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Second Generation Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Second Generation Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Second Generation Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Decongestants Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Decongestants Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Decongestants Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Leukotriene Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Leukotriene Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Leukotriene Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Mast Cell Stabilizers Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Mast Cell Stabilizers Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Mast Cell Stabilizers Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 26. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Nasal Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Nasal Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Nasal Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Drops Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Drops Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Drops Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Spray Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Spray Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Spray Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Ophthalmic Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Ophthalmic Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Ophthalmic Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 48. Global Drug Allergies Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Drug Allergies Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Drug Allergies Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Eye Allergies Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Eye Allergies Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Eye Allergies Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Food Allergies Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Food Allergies Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Food Allergies Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Latex Allergy Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Latex Allergy Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Latex Allergy Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Respiratory Allergies Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Respiratory Allergies Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Respiratory Allergies Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Allergic Asthma Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Allergic Asthma Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Allergic Asthma Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Allergic Rhinitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Allergic Rhinitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Allergic Rhinitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Skin Allergies Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Skin Allergies Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Skin Allergies Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 73. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Allergy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Allergy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. Europe Allergy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Europe Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 101. Europe Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 102. Europe Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 103. Europe Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 104. Europe Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 105. Europe Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 106. Europe Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 107. Europe Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 108. North America Allergy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. North America Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 110. North America Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 111. North America Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 112. North America Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 113. North America Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 114. North America Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 115. North America Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 116. North America Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Latin America Allergy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Latin America Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 119. Latin America Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 120. Latin America Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 121. Latin America Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 122. Latin America Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 123. Latin America Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 124. Latin America Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 125. Latin America Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. Africa Allergy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Africa Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 128. Africa Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 129. Africa Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 130. Africa Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 131. Africa Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 132. Africa Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 133. Africa Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 134. Africa Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. Middle East Allergy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Middle East Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 137. Middle East Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 138. Middle East Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 139. Middle East Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 140. Middle East Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 141. Middle East Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 142. Middle East Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 143. Middle East Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 144. Global Allergy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. NATO Allergy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. NATO Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 147. NATO Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 148. NATO Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 149. NATO Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 150. NATO Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 151. NATO Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 152. NATO Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 153. NATO Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. G7 Allergy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. G7 Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 156. G7 Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 157. G7 Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. G7 Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 159. G7 Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 160. G7 Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 161. G7 Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 162. G7 Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. BRICS Allergy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. BRICS Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 165. BRICS Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 166. BRICS Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. BRICS Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 168. BRICS Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 169. BRICS Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 170. BRICS Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 171. BRICS Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. European Union Allergy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 173. European Union Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 174. European Union Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 175. European Union Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 176. European Union Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 177. European Union Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 178. European Union Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 179. European Union Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 180. European Union Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. ASEAN Allergy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. ASEAN Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 183. ASEAN Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 184. ASEAN Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 185. ASEAN Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 186. ASEAN Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 187. ASEAN Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 188. ASEAN Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 189. ASEAN Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. GCC Allergy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. GCC Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 192. GCC Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 193. GCC Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 194. GCC Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 195. GCC Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 196. GCC Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 197. GCC Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 198. GCC Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. Global Allergy Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 200. China Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 201. China Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 202. China Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 203. China Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 204. China Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 205. China Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 206. China Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 207. China Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 208. China Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. United States Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 210. United States Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 211. United States Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 212. United States Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. United States Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 214. United States Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 215. United States Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 216. United States Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 217. United States Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. Japan Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 219. Japan Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 220. Japan Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 221. Japan Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 222. Japan Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 223. Japan Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 224. Japan Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 225. Japan Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 226. Japan Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 227. India Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 228. India Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 229. India Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 230. India Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. India Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 232. India Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 233. India Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 234. India Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 235. India Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Germany Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 237. Germany Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 238. Germany Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 239. Germany Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 240. Germany Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 241. Germany Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 242. Germany Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 243. Germany Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 244. Germany Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. United Kingdom Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 246. United Kingdom Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 247. United Kingdom Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 248. United Kingdom Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 249. United Kingdom Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 250. United Kingdom Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 251. United Kingdom Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 252. United Kingdom Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 253. United Kingdom Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. Australia Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 255. Australia Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 256. Australia Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 257. Australia Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 258. Australia Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 259. Australia Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 260. Australia Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 261. Australia Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 262. Australia Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. France Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 264. France Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 265. France Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 266. France Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 267. France Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 268. France Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 269. France Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 270. France Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 271. France Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 272. South Korea Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 273. South Korea Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 274. South Korea Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 275. South Korea Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 276. South Korea Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 277. South Korea Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 278. South Korea Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 279. South Korea Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 280. South Korea Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 281. Italy Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 282. Italy Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 283. Italy Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 284. Italy Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 285. Italy Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 286. Italy Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 287. Italy Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 288. Italy Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 289. Italy Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 290. Canada Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 291. Canada Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 292. Canada Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 293. Canada Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 294. Canada Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 295. Canada Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 296. Canada Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 297. Canada Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 298. Canada Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Russia Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 300. Russia Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 301. Russia Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 302. Russia Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 303. Russia Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 304. Russia Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 305. Russia Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 306. Russia Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 307. Russia Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 308. Brazil Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 309. Brazil Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 310. Brazil Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 311. Brazil Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 312. Brazil Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 313. Brazil Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 314. Brazil Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 315. Brazil Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 316. Brazil Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 317. Mexico Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 318. Mexico Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 319. Mexico Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 320. Mexico Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 321. Mexico Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 322. Mexico Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 323. Mexico Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 324. Mexico Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 325. Mexico Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 326. Spain Allergy Drugs Market Size, 2017-2032 (USD Million)
TABLE 327. Spain Allergy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 328. Spain Allergy Drugs Market Size, by Antihistamines, 2017-2032 (USD Million)
TABLE 329. Spain Allergy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 330. Spain Allergy Drugs Market Size, by Nasal, 2017-2032 (USD Million)
TABLE 331. Spain Allergy Drugs Market Size, by Allergy Indication, 2017-2032 (USD Million)
TABLE 332. Spain Allergy Drugs Market Size, by Respiratory Allergies, 2017-2032 (USD Million)
TABLE 333. Spain Allergy Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 334. Spain Allergy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 335. Global Allergy Drugs Market Share, by Key Player, 2025
TABLE 336. Global Allergy Drugs Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Alcon Inc.
  • ALK-Abelló A/S
  • Allergopharma GmbH & Co. KG
  • Allergy Therapeutics plc
  • Apotex Inc.
  • Bayer AG
  • Biomay AG
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Circassia Group plc
  • DBV Technologies S.A.
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd
  • Faes Farma, S.A.
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • HAL Allergy B.V.
  • Inmunotek S.L.
  • Johnson & Johnson
  • LETI Pharma, S.L.U.
  • Meda Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Prestige Brands Holdings Inc
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Stallergenes Greer International AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torii Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages183
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 27.08 Billion
Forecasted Market Value ( USD ) by 2032 $ 40.03 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Asia-Pacific Allergy Treatment Market Outlook, 2030 - Product Image

Asia-Pacific Allergy Treatment Market Outlook, 2030

  • Report
  • 96 Pages
  • Asia Pacific
From
Anti-Allergy Drugs - Global Strategic Business Report - Product Image

Anti-Allergy Drugs - Global Strategic Business Report

  • Report
  • 168 Pages
  • Global
From
Allergic Rhinitis Drugs Market - Global Forecast 2026-2032 - Product Image

Allergic Rhinitis Drugs Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Allergy Treatment Market - Global Forecast 2026-2032 - Product Image

Allergy Treatment Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Allergic Rhinitis Drugs - Global Strategic Business Report - Product Image

Allergic Rhinitis Drugs - Global Strategic Business Report

  • Report
  • 563 Pages
  • Global
From

About the Allergy Drugs Market

The Allergy Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of medications used to treat allergies. Allergy drugs are used to treat a wide range of conditions, including hay fever, asthma, eczema, and food allergies. These drugs can be administered orally, topically, or through injections. Commonly used allergy drugs include antihistamines, decongestants, corticosteroids, and leukotriene modifiers. The Allergy Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Sanofi, Pfizer, Novartis, and Johnson & Johnson. These companies are constantly developing new drugs and treatments to meet the needs of allergy sufferers. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.